Breast (Edinburgh, Scotland)
Adjuvant ovarian function suppression and aromatase inhibitors in premenopausal patients with hormone receptor and HER2 positive breast cancer, by timing of chemotherapy and trastuzumab and response to neoadjuvant therapy.
Ayelet Shai, Hans Wildiers, Claudio Venieri, Katarzyna Pogoda, Barbro Linderholm, Matteo Lambertini, Leonor Matos, Eleonora De Maio D'Esposito, Nawale Hajjaji, Erika Matos, Lucía González Cortijo, Giuseppe Fotia, Ana Fortuna, Tal Sella, Helena Gouveia
Published: 202510.1016/j.breast.2025.104669
Abstract
BACKGROUND: The benefit of adjuvant ovarian function suppression (OFS) and aromatase inhibitors (AI) in premenopausal patients with hormone receptor positive, HER2 positive (HR+/HER2+) breast cancer (BC) is unclear. We aimed to investigate this quest…
Preview only. Read the full abstract at the source